Bayer Loses Bid To Block J&J's Cancer Drug Survival Claims
A Manhattan federal judge Friday refused to block Johnson & Johnson from advertising its prostate cancer drug as having a lower risk of death compared with Bayer's medication, saying Bayer has...To view the full article, register now.
Already a subscriber? Click here to view full article